NCT06894277 Internet-based Talking About Risk and Adolescent Choices: Health and Emotion Regulation Options
| NCT ID | NCT06894277 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Klein Buendel, Inc. |
| Condition | Risky Sexual Behavior |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2026-06-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-04-01 with a primary completion date of 2026-06-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Using the efficacious iTRAC intervention to enhance emotion regulation competencies as a foundation, this study will create and test iTRAC-HERO to teach emotion regulation skills in the context of sexual health education.
Eligibility Criteria
Inclusion Criteria: * Attending 7th grade * Between 12 and 14 years old * Parent/guardian speaks English or Spanish * Attending participating school Exclusion Criteria: * Unable to read at a 4th grade level * Have a sibling who has participated in the study * Have a development disorder
Contact & Investigator
Christopher Houck, PhD
PRINCIPAL INVESTIGATOR
Rhode Island Hospital
Frequently Asked Questions
Who can join the NCT06894277 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 14 Years, studying Risky Sexual Behavior. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06894277 currently recruiting?
Yes, NCT06894277 is actively recruiting participants. Contact the research team at jberteletti@kleinbuendel.com for enrollment information.
Where is the NCT06894277 trial being conducted?
This trial is being conducted at Golden, United States.
Who is sponsoring the NCT06894277 clinical trial?
NCT06894277 is sponsored by Klein Buendel, Inc.. The principal investigator is Christopher Houck, PhD at Rhode Island Hospital. The trial plans to enroll 120 participants.